The Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Lincoln Pharmaceuticals to clarify why its financial results for the quarter ended 30 September 2025 were not submitted in the format prescribed by SEBI under Regulation 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015. The exchange has flagged this as a compliance issue and is awaiting the company's response. No financial numbers or specific discrepancies have been mentioned in the filing. The matter appears to be procedural in nature rather than related to the accuracy of the reported numbers.
This is a routine format-related clarification request and is unlikely to materially affect the stock or shareholders. Investors should watch for the company's reply, as unresolved SEBI clarifications can sometimes lead to further regulatory action or short-term negative sentiment.